Is retatrutide better than tirzepatide?

On raw weight loss the published numbers favor retatrutide: up to 24.2% at 48 weeks in Jastreboff 2023 against about 15% for tirzepatide in its pivotal trial. On everything you can act on, tirzepatide wins. It scores 6.1 against 5.6, takes five of nine use cases with four ties and no retatrutide wins, and it is the only one of the two that legally exists as a medicine.

Should I wait for retatrutide to be approved?

Not if you have metabolic disease now. Retatrutide's Phase 3 program is still running and full effect takes about 48 weeks once you start, against 20 for tirzepatide. Waiting means untreated obesity, diabetes or sleep apnea in the meantime. Start tirzepatide, hold the 16-week assessment window, and revisit if retatrutide is approved with a clean label.

Can I buy retatrutide legally?

No. FDA states retatrutide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding. There is no pharmacy or compounding route anywhere. Outside a Lilly TRIUMPH or TRANSCEND trial the only supply is a research-chemical vial sold not for human use, where identity, concentration and sterility depend entirely on the vendor.

Can I take retatrutide and tirzepatide together?

No, and there is no mechanism argument for it. Retatrutide activates GLP-1R, GIPR and the glucagon receptor. Tirzepatide activates the first two. The overlap is redundant at two of three receptors, so combining them multiplies the gastrointestinal burden and the dose-related heart-rate concern without adding a pathway.

Which one costs more per month?

It depends on the retatrutide dose, and neither figure is a measured price. Tirzepatide is an ESTIMATED $299 to $449 a month through LillyDirect self-pay, priced 2026-09-07. Retatrutide research vials are an ESTIMATED $128 to $320 a month at 4 mg weekly and $384 to $960 at 12 mg, priced the same day. Cheaper at a low dose, roughly double at the dose that produced the headline results.

Does retatrutide protect the liver better than tirzepatide?

Possibly, and it is unproven. Retatrutide's glucagon arm is designed to raise hepatic fat oxidation, and Sanyal 2024 measured liver-fat reductions in MASLD directly. That is why the subratings land at 8.0 against tirzepatide's 8.3 despite the gap in evidence volume. Sanyal 2024 is a Phase 2a substudy, below the source report's own sample threshold. Treat it as a promising signal rather than a reason to wait.

Who should not take either one?

Anyone with a personal or family history of medullary thyroid carcinoma or MEN2, prior pancreatitis, severe gastroparesis, or who is pregnant or planning conception without a washout plan. Retatrutide adds an active eating disorder, advanced kidney disease and significant cardiovascular disease without specialist oversight. Tirzepatide adds gallbladder disease and upcoming anesthesia without a fasting plan. Tested athletes should treat both as anti-doping risks.

Head-to-Head Comparison

Retatrutide vs Tirzepatide: Which Is Better for Weight Loss?

Should I wait for retatrutide or start tirzepatide now?

Reviewed 09/07/2026

Start tirzepatide. It scores 6.1 against retatrutide's 5.6, and the gap is mostly availability and evidence maturity rather than weaker biology. Retatrutide is not approved anywhere, cannot legally be compounded, and outside a Lilly trial the only supply is a research-chemical vial.

Tirzepatide 6.1, retatrutide 5.6. Retatrutide loses 64 of the 66 shared use cases on subratings alone.
Retatrutide's raw weight-loss numbers are bigger. Jastreboff 2023 reported up to 24.2% at 48 weeks in a Phase 2 trial, against about 15% for tirzepatide in the pivotal Phase 3.
That does not make it the better choice today. FDA says retatrutide has not been found safe and effective for any condition and cannot be used in compounding.
Retatrutide has no completed cardiovascular outcomes trial, no published Phase 3, and no pharmacy channel. Tirzepatide has all three.
Costs are not comparable. Tirzepatide is an ESTIMATED $299 to $449 a month through LillyDirect self-pay. Retatrutide is an ESTIMATED $130 to $960 a month of not-for-human-use vials.
Both take the same 16 weeks to assess and neither protects muscle. Resistance training and protein are part of the dose on either one.

At a Glance

Option A

Retatrutide

5.6 / 10 🤷 Neutral

Upside

Efficacy 5.0
Breadth 4.0
Evidence 3.4
Speed 3.8
Durability 2.0
Bioindividuality 4.8

Downside

Safety Risk 4.0
Side Effects 2.6
Cost 2.4
Effort 1.5
Opportunity Cost 2.2
Dependency 3.6
Reversibility 1.7

Best at:

Metabolic Health 8.5
Liver Detox 8.0
Blood Sugar 8.0
Body Composition 7.5

Investigational GLP-1, GIP and glucagon triple agonist. BioHarmony 5.6, neutral.

Read full BioHarmony report →

Option B

Tirzepatide

6.1 / 10 Worth trying

Upside

Efficacy 5.0
Breadth 4.8
Evidence 4.4
Speed 4.2
Durability 2.0
Bioindividuality 4.4

Downside

Safety Risk 4.0
Side Effects 2.4
Cost 2.2
Effort 1.6
Opportunity Cost 2.1
Dependency 3.5
Reversibility 1.7

Best at:

Blood Sugar 9.2
Body Composition 9.0
Metabolic Health 8.7
Liver Detox 8.3

Approved dual GIP and GLP-1 agonist. BioHarmony 6.1, worth trying.

Read full BioHarmony report →

Head-to-Head Verdict

Use Case	Winner	Rationale
Body Composition	Tirzepatide	Tirzepatide wins on evidence you can act on, not effect size. Subratings are 9.0 against 7.5, and retatrutide's report calls its 7.5 a maturity discount: Jastreboff 2023 reported up to 24.2% loss at 48 weeks, and Xie 2024 ranked it first of seven agents. That ranking is indirect. Tirzepatide's 15% comes from a pivotal Phase 3.
Blood Sugar	Tirzepatide	Tirzepatide, 9.2 against 8.0. Frias 2021 puts tirzepatide's HbA1c reduction at about 1.5% in Phase 3 type 2 diabetes, with Tang 2022 confirming class-leading glycemic effects across doses. Rosenstock 2023 reported HbA1c down as much as 2.02% on retatrutide, a larger number from a Phase 2 trial of 24 weeks. Lilly's TRANSCEND-T2D-1 Phase 3 topline is a press release, not peer-reviewed data.
Metabolic Health	Tie	Call this even on biology. Retatrutide 8.5, tirzepatide 8.7, a 0.2 gap that means nothing. Both hit appetite, glucose, waist circumference and cardiometabolic markers, and both bodies of evidence sit at a moderate tier. Availability breaks the tie, not the score: one of them has an approved label and a pharmacy, the other has a Phase 3 program that has not published.
Cardiovascular	Tirzepatide	Tirzepatide, 7.8 against 6.0, and the gap is a completed trial. Packer 2025 showed reduced worsening heart-failure events in HFpEF with obesity. Retatrutide's report says risk markers likely move favorably but no cardiovascular outcomes trial exists. It also flags a dose-related heart-rate rise from Jastreboff 2023.
Liver Detox	Tie	Honest tie, and the row where retatrutide's mechanism argues for itself. It scores 8.0 because the glucagon arm is designed to raise hepatic fat oxidation, and Sanyal 2024 measured liver-fat reductions in MASLD directly. Tirzepatide's 8.3 rests on indirect evidence: weight loss and insulin-resistance reduction, with histologic outcomes still limited.
Respiratory	Tirzepatide	Tirzepatide, 7.5 against 3.5, the widest actionable gap in the matrix. Tirzepatide has an approved obesity-related obstructive sleep apnea indication behind SURMOUNT-OSA (Malhotra 2024). Retatrutide has OSA inside the TRIUMPH Phase 3 program and nothing published. If sleep apnea is the reason you are here, waiting costs you the one indication that is already settled.
Healthspan	Tirzepatide	Tirzepatide, 7.0 against 4.5. The Cochrane review of 9 studies and 7,111 adults (Franco 2025) supports medium-term weight loss likely sustained beyond two years, and Jastreboff 2025 followed 1,032 adults with obesity and prediabetes for 176 weeks with reduced progression to type 2 diabetes. Retatrutide has no long-term morbidity, mortality, dementia or frailty data at all.
Bone Joint	Tie	The one row where retatrutide's subrating is higher, 4.5 against 3.0, and it is still not a reason to wait. That score rests on Lilly's TRIUMPH-4 topline reporting WOMAC pain improvement in knee osteoarthritis, not peer-reviewed at audit close. Tirzepatide's 3.0 reflects real bone-loss and fracture concern during rapid loss. Neither is a joint therapy.
Muscle Growth	Tie	Retatrutide 1.0, tirzepatide 2.5, both near the floor and neither a reason to pick one. Rapid weight loss takes lean mass on either drug unless you actively defend it. Both source reports put progressive resistance training and a protein target inside the protocol rather than beside it, and retatrutide's report adds bone risk to the same list.

Cost Comparison

Intervention	Monthly Cost	Notes
Retatrutide	$130 to $960	ESTIMATE, priced 2026-09-07, research-chemical channel. Research-peptide 10 mg vials run about $80 to $200. At 4 mg weekly, which is 16 mg a month, that is $128 to $320. At 12 mg weekly, 48 mg a month, it is $384 to $960. No legal pharmacy channel exists, so this is the price of a vial labelled not for human use, with vendor-dependent purity on top.
Tirzepatide	$299 to $449	ESTIMATE, priced 2026-09-07, telehealth and manufacturer self-pay channel. LillyDirect self-pay Zepbound vials are $299 per 28 days at 2.5 mg, $399 at 5 mg and $449 at 7.5 through 15 mg, which covers the whole standard titration. Branded pharmacy retail without coverage is far higher. A channel estimate, not a measured price you are guaranteed to pay.
The difference	Not a like-for-like comparison at any dose	At a 4 mg retatrutide dose the vial route looks cheaper than tirzepatide, $128 to $320 against $299 to $449. At the 12 mg dose that produced the headline weight loss it runs to $960, more than double.Both figures are estimates priced 2026-09-07. The real difference is what you are buying. One is a manufactured pharmacy product with a label. The other is a research vial with no product standard, so cheaper here does not mean equivalent.

When to Switch

Both drugs change appetite inside about a week and both carry the same 16-week assessment window, so early feel decides nothing. Judge at 16 weeks. The real timing difference is what happens after: tirzepatide reaches full effect around week 20, retatrutide around week 48, so a retatrutide decision needs roughly a year of exposure to a drug with no approved label. That is the case for starting tirzepatide now.

Do not run them together: retatrutide's target set contains tirzepatide's entirely, so the pairing is redundant at two of three receptors and only stacks the gastrointestinal burden.

If retatrutide is approved with a clean label, the trigger to move is a body-composition or liver-fat plateau at 15 mg tirzepatide through a full 16-week window with protein and resistance training already in place. Stop one, start the other at its lowest step, and expect to re-climb the ladder. Until then the only defensible route to retatrutide is a Lilly trial, where product, titration, labs and adverse-event tracking are supplied.

Who Should Pick What?

Adult with a BMI over 35 who wants to start treatment this month

Tirzepatide

It is the only one of the two you can obtain legitimately. Body composition 9.0 against 7.5, an approved label, a Cochrane review behind it and a manufacturer self-pay channel. Waiting for a better molecule costs you a year of untreated metabolic disease.

Type 2 diabetic with poor control despite standard therapy

Tirzepatide

Blood sugar 9.2 against 8.0, from Phase 3 data (Frias 2021) rather than a 24-week Phase 2. Retatrutide's larger HbA1c number is real and unfinished. A drug with no label is the wrong place to run your glycemic control.

Adult with obesity and diagnosed obstructive sleep apnea

Tirzepatide

Respiratory 7.5 against 3.5 and sleep quality 8.0 against 3.5. Tirzepatide has an approved obesity-related OSA indication behind SURMOUNT-OSA. Retatrutide's OSA evidence is a Phase 3 arm still running. Keep using your PAP machine until a repeat sleep study says otherwise.

Adult with MASLD or high measured liver fat

Tirzepatide

The liver row is an honest tie at 8.0 against 8.3, and retatrutide's glucagon arm is the more interesting mechanism, with Sanyal 2024 measuring liver fat directly. It is still a Phase 2a substudy. Treat the liver now with the drug that exists and re-read this row when Phase 3 publishes.

Eligible for a Lilly TRIUMPH or TRANSCEND trial and willing to enrol

Retatrutide

This is the only defensible route to retatrutide. A trial supplies manufactured product, formal titration, laboratory monitoring and adverse-event tracking, which is exactly what the research-vial market does not. Retatrutide's own report names trial enrolment as its best-for population.

Thinking about buying a retatrutide research vial online

Tie

Neither. FDA says retatrutide has not been found safe and effective for any condition and cannot be used in compounding, so the vial has no product standard behind its label. If you want triple-agonist results today you cannot have them safely. Take tirzepatide or wait for approval.

Metabolically healthy, chasing a cosmetic 15 pounds

Tie

Neither. Both reports restrict the risk-benefit to real metabolic pathology, both carry medullary thyroid carcinoma and MEN2 contraindications, both exclude pregnancy or planned pregnancy, and neither protects lean mass. This is the row where the honest answer is to not start.

Research Highlights

Mechanism Difference
The relationship between these two molecules is redundant, not complementary. Tirzepatide activates GLP-1R and GIPR. Retatrutide activates GLP-1R, GIPR and the glucagon receptor, so its target set contains tirzepatide's entirely.The only mechanistic difference is the third arm, glucagon receptor agonism, intended to raise hepatic fat oxidation and energy expenditure on top of the shared appetite and glycemic effects. That is why running them together makes no sense and why retatrutide's distinctive claim is a liver and energy-expenditure claim.
Safety Comparison
Both score 4.0 out of 5.0 on safety risk and sit within 0.2 on side-effect profile, and they share most exclusions: medullary thyroid carcinoma or MEN2 history, prior pancreatitis, severe gastroparesis, and pregnancy or planned pregnancy.The difference is what is unknown. Tirzepatide's risks are label-documented, including gallbladder disease and dehydration-driven kidney risk during severe gastrointestinal reactions. Retatrutide adds dose-related heart-rate increases, dysesthesia, an active eating disorder exclusion, and no long-term safety exposure at all.
Cost Comparison
Tirzepatide runs an ESTIMATED $299 to $449 a month through LillyDirect self-pay, priced 2026-09-07, covering the whole 2.5 mg to 15 mg titration. Retatrutide has no pharmacy price because it has no pharmacy.The ESTIMATE for research vials, also priced 2026-09-07, is $128 to $320 a month at 4 mg weekly and $384 to $960 at the 12 mg dose that produced the headline results. Cheaper at the low dose, more than double at the effective one, and unverified purity at both.
Evidence Maturity
Retatrutide's lower subratings are largely an evidence-maturity discount rather than a verdict on the drug. Its report says so directly: the best evidence is Phase 2 metabolic data, so the scores are directional rather than settled.Read that carefully before you conclude the molecule underperforms. Jastreboff 2023 reported up to 24.2% body-weight loss at 48 weeks, larger than tirzepatide's pivotal 15%, and Xie 2024 ranked retatrutide first among seven agents in an indirect network meta-analysis of 27 RCTs. The gap is publication and approval, not effect.
Editorial Verdict
Start tirzepatide. It scores 6.1 against retatrutide's 5.6 and wins five of the nine use cases outright, with four honest ties and no retatrutide wins. More to the point, it has an approved label, a pharmacy channel and Phase 3 outcome data in three organ systems.Retatrutide is the more ambitious molecule and may well be the better one by 2028. Today it is unapproved anywhere, cannot legally be compounded, and outside a Lilly trial arrives as a research vial with vendor-dependent purity. Treat approval as the trigger, not the headline percentage.

Frequently Asked Questions

Is retatrutide better than tirzepatide?: On raw weight loss the published numbers favor retatrutide: up to 24.2% at 48 weeks in Jastreboff 2023 against about 15% for tirzepatide in its pivotal trial. On everything you can act on, tirzepatide wins. It scores 6.1 against 5.6, takes five of nine use cases with four ties and no retatrutide wins, and it is the only one of the two that legally exists as a medicine.
Should I wait for retatrutide to be approved?: Not if you have metabolic disease now. Retatrutide's Phase 3 program is still running and full effect takes about 48 weeks once you start, against 20 for tirzepatide.Waiting means untreated obesity, diabetes or sleep apnea in the meantime. Start tirzepatide, hold the 16-week assessment window, and revisit if retatrutide is approved with a clean label.
Can I buy retatrutide legally?: No. FDA states retatrutide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding. There is no pharmacy or compounding route anywhere. Outside a Lilly TRIUMPH or TRANSCEND trial the only supply is a research-chemical vial sold not for human use, where identity, concentration and sterility depend entirely on the vendor.
Can I take retatrutide and tirzepatide together?: No, and there is no mechanism argument for it. Retatrutide activates GLP-1R, GIPR and the glucagon receptor. Tirzepatide activates the first two. The overlap is redundant at two of three receptors, so combining them multiplies the gastrointestinal burden and the dose-related heart-rate concern without adding a pathway.
Which one costs more per month?: It depends on the retatrutide dose, and neither figure is a measured price. Tirzepatide is an ESTIMATED $299 to $449 a month through LillyDirect self-pay, priced 2026-09-07.Retatrutide research vials are an ESTIMATED $128 to $320 a month at 4 mg weekly and $384 to $960 at 12 mg, priced the same day. Cheaper at a low dose, roughly double at the dose that produced the headline results.
How long before I know whether it is working?: Sixteen weeks on either drug. Both give a first noticeable appetite change in about a week, and both source reports set the same 16-week assessment window, so early feel tells you nothing. After that they diverge: tirzepatide reaches full effect around week 20, retatrutide around week 48.
Does retatrutide protect the liver better than tirzepatide?: Possibly, and it is unproven. Retatrutide's glucagon arm is designed to raise hepatic fat oxidation, and Sanyal 2024 measured liver-fat reductions in MASLD directly. That is why the subratings land at 8.0 against tirzepatide's 8.3 despite the gap in evidence volume.Sanyal 2024 is a Phase 2a substudy, below the source report's own sample threshold. Treat it as a promising signal rather than a reason to wait.
Who should not take either one?: Anyone with a personal or family history of medullary thyroid carcinoma or MEN2, prior pancreatitis, severe gastroparesis, or who is pregnant or planning conception without a washout plan.Retatrutide adds an active eating disorder, advanced kidney disease and significant cardiovascular disease without specialist oversight. Tirzepatide adds gallbladder disease and upcoming anesthesia without a fasting plan. Tested athletes should treat both as anti-doping risks.

Evidence Sources

RCT Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (2023) Phase 2 obesity RCT; up to 24.2% body-weight loss at 48 weeks, with dose-related gastrointestinal adverse events and heart-rate increases.
RCT Retatrutide for people with type 2 diabetes: randomized phase 2 trial (2023) Phase 2 type 2 diabetes RCT; HbA1c reduction up to 2.02% at 24 weeks and body-weight loss up to 16.94% at 36 weeks.
RCT Triple hormone receptor agonist retatrutide for MASLD: randomized phase 2a trial (2024) Phase 2a MASLD substudy with a large liver-fat reduction signal. Below the source report's Track 1 sample threshold.
Meta-analysis Seven GLP-1 receptor agonists and polyagonists for weight loss: updated network meta-analysis (2024) 27 RCTs, 15,584 participants. Retatrutide 12 mg and 8 mg ranked strongest for weight loss in an indirect comparison, not a direct head-to-head trial.
Protocol TRIUMPH registrational clinical trials rationale and design (2026) Phase 3 program design for obesity, obstructive sleep apnea and knee osteoarthritis. A design source, not outcomes proof.
Press release Lilly TRIUMPH-4 topline obesity and knee osteoarthritis Phase 3 press release (2025) Company-reported topline: up to 28.7% body-weight loss and WOMAC pain improvement at 68 weeks. Not peer-reviewed at audit close.
Regulatory FDA: concerns with unapproved GLP-1 drugs used for weight loss (2026) FDA states retatrutide cannot be used in compounding, is not a component of an FDA-approved drug, and has not been found safe and effective for any condition.
RCT Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (2022) Pivotal obesity RCT; substantial body-weight reduction versus placebo in adults with obesity or overweight without diabetes.
RCT Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) (2021) Greater HbA1c and body-weight reduction with tirzepatide than semaglutide 1 mg, establishing tirzepatide's Phase 3 glycemic position.
Systematic review Tirzepatide for adults living with obesity, Cochrane Database of Systematic Reviews (2025) 9 studies, 7,111 adults. Likely medium-term weight loss versus placebo, likely sustained beyond two years. All included studies manufacturer-funded.
RCT Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 extension) (2025) 1,032 participants with obesity and prediabetes; sustained weight loss and reduced or delayed progression to type 2 diabetes over 176 weeks.
RCT Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (2025) 731 participants; reduced composite clinical endpoint or worsening heart-failure events and improved health status versus placebo.
RCT Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4) (2023) Randomized withdrawal; continued tirzepatide maintained or augmented weight reduction while switching to placebo led to regain.
Label DailyMed MOUNJARO tirzepatide prescribing information (2026) Official labeling source for the boxed warning, contraindications, dosing, pregnancy precautions and adverse reactions.

Glossary

Quick reference for the medical and technical terms used in this comparison.

GLP-1 Glucagon-Like Peptide-1: An incretin hormone that raises glucose-dependent insulin secretion, slows gastric emptying and suppresses appetite. Both drugs act on its receptor.
GIP Glucose-Dependent Insulinotropic Polypeptide: The second incretin hormone. Both drugs activate its receptor, which amplifies insulin signaling and affects how adipose tissue handles energy.
GCGR Glucagon Receptor: The third receptor, activated by retatrutide only. In this drug design it is used to raise hepatic fat oxidation and energy expenditure.
Triple agonist Triple receptor agonist: One molecule activating three receptor systems. Retatrutide targets GLP-1R, GIPR and the glucagon receptor. Tirzepatide targets the first two.
HbA1c Glycated Hemoglobin: A two to three month average of blood glucose and the primary endpoint in most diabetes trials, including Frias 2021 and Rosenstock 2023.
MASLD Metabolic Dysfunction-Associated Steatotic Liver Disease: Fatty liver disease linked to metabolic dysfunction, formerly NAFLD. The population in Sanyal 2024's retatrutide liver-fat substudy.
MTC Medullary Thyroid Carcinoma: The rare thyroid cancer named in tirzepatide's boxed warning. A personal or family history of it rules out both drugs.
MEN2 Multiple Endocrine Neoplasia type 2: A hereditary syndrome that raises MTC risk. A hard contraindication on both source reports.
OSA Obstructive Sleep Apnea: Airway collapse during sleep. Tirzepatide has an approved obesity-related OSA indication. Retatrutide has an OSA arm inside TRIUMPH.
HFpEF Heart Failure with Preserved Ejection Fraction: Heart failure where the heart pumps normally but fills poorly. Tirzepatide has a dedicated trial here (Packer 2025). Retatrutide has none.
TRIUMPH Lilly's Phase 3 retatrutide program: The registrational program in obesity and weight-related complications, including sleep apnea and knee osteoarthritis. Still reading out.
Dysesthesia Dysesthesia: Abnormal sensation such as tingling or burning. A reported retatrutide side effect that does not appear on tirzepatide's list.

Nick Urban Health Optimization Researcher & CHEK Holistic Lifestyle Coach Level 2

I have spent over a decade testing metabolic interventions on myself and screening them for clients and podcast guests

Reviewed Sep 7, 2026 · next review Dec 6, 2026

Find which one fits your biology

Take the BioHarmony Quiz